CSF ‐Compartmentalized Antibody Glycoprofiles in NMDAR Encephalitis Associate with Etiology and Functional Recovery
Open Access
- 18 February 2026
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1468-1479
Abstract
Objective: To characterize Fc‐glycosylation profiles in patients with anti‐N‐methyl‐D‐aspartate receptor encephalitis (NMDARe) and assess their association with antibody compartmentalization (cerebrospinal fluid [CSF] vs serum), disease triggers (viral, tumor‐related or idiopathic), and 1‐year outcomes. Methods: We analyzed immunoglobulin (Ig) G1 and IgG2/3 Fc‐glycosylation by liquid chromatography–mass spectrometry in paired serum/CSF samples from 50 age‐ and sex‐matched patients with NMDARe identified in IDIBAPS/Hospital Clinic of Barcelona database and the Spanish study on herpes encephalitis. Patients were classified by disease trigger as post‐herpetic, tumor‐related, or idiopathic. One‐year outcomes were defined as good (modified Rankin Scale [mRS] ≤2) or poor (≥3). Fc glycoprofiles were quantified for fucosylation, sialylation, galactosylation, and bisecting N‐acetylglucosamination. Results: Across IgG subclasses (IgG1–3), CSF antibodies showed significantly reduced sialylation and galactosylation compared to serum ( p < 0.0001), indicating a pro‐inflammatory compartmentalized response within the central nervous system. These inflammatory Fc‐glycoforms were predominant in post‐herpetic cases of NMDARe ( p < 0.01) compared to tumor‐related and idiopathic forms, suggesting that viral‐induced NMDAR may alter antibody Fc‐glycosylation via B‐cell glycosylation pathway modulation. Furthermore, reduced sialylation, galactosylation and fucosylation in CSF and serum were associated with poor 1‐year outcomes ( p < 0.05), suggesting that compartmentalized inflammation and enhanced innate immune activation, including natural killer (NK) cell–mediated cytotoxicity driven by afucosylated antibodies, might contribute to neurological dysfunction. Interpretation: In NMDARe, CSF Fc‐glycosylation profiles are both compartment‐ and trigger‐specific. Because glycan signatures shape innate immune interactions (e.g., with NK cells), these findings highlight distinct pathogenic mechanisms and support Fc‐glycosylation profiling as a potential prognostic biomarker. ANN NEUROL 2026;99:1468–1479Keywords
This publication has 35 references indexed in Scilit:
- Humoral signatures of Caspr2-antibody spectrum disorder track with clinical phenotypes and outcomesMed, 2024
- IgG glycans in health and disease: Prediction, intervention, prognosis, and therapyBiotechnology Advances, 2023
- Humoral signatures of MOG-antibody-associated disease track with age and disease activityCell Reports Medicine, 2023
- Antibody glycosylation in autoimmune diseasesAutoimmunity Reviews, 2021
- Antibody glycosylation in inflammation, disease and vaccinationSeminars in Immunology, 2018
- Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitisJournal of Neuroimmunology, 2016
- Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective studyThe Lancet Neurology, 2014
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratomaActa Neuropathologica, 2009
- Coming of age: carbohydrates and immunityEuropean Journal of Immunology, 2005